Hetero, Cipla get nod to make remdesivir to treat Indian COVID-19 patients
Cipla and Hetero Drugs have been granted emergency use approval of antiviral drug remdesivir by drug regulatory body CDSCO. The approvals will allow them to manufacture and supply remdesivir for treatment of suspected or confirmed
Cipla and Hetero Drugs have been granted emergency use approval of antiviral drug remdesivir by drug regulatory body CDSCO. The approvals will allow them to manufacture and supply remdesivir for treatment of suspected or confirmed cases of COVID-19 “with severe disease”. The drug will be made available to Maharashtra and Delhi first, likely costing between ₹5,000-₹6,000 per dose, Hetero said.
